(Q58011173)

English

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

article

In more languages

Statements

scholarly article

0 references

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation (English)

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

M Hamadani

9

0 references

author name string

F T Awan

1

0 references

S Osman

2

0 references

S T Kochuparambil

3

0 references

L Gibson

4

0 references

S C Remick

5

0 references

J Abraham

6

0 references

M Craig

7

0 references

A Jillella

8

0 references

language of work or name

0 references

publication date

28 February 2011

0 references

Bone Marrow Transplantation

0 references

47

0 references

1

0 references

146-148

0 references

https://scigraph.springernature.com/pub.10.1038/bmt.2011.18

0 references

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

21 January 2018

Myeloablative therapy for primary resistant multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

21 January 2018

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

21 January 2018

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

21 January 2018

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

21 January 2018

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

7 January 2021

based on heuristic

inferred from DOI database lookup

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.18

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2011.18

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58011173&oldid=1522548911"